Acquisition History / Majesty II Pte. Ltd. / AI Lenarco Midco Ltd.

Majesty II Pte. Ltd. Acquires AI Lenarco Midco Ltd.

Announced January 2024 — Price not disclosed (CCI combination order)

Majesty II Pte. Ltd.Pharma services2024

What happened

Holding company of an Indian pharma/specialty business Acquired through Majesty II Pte. Ltd., a vehicle of PAG; Advent International; Nuvama Private Investment Trust; Ashoka India Equity Investment Trust plc. Source: https://www.cci.gov.in/images/summaryorders/en/summary1733906432.pdf

Acquirer
Majesty II Pte. Ltd.
Target
AI Lenarco Midco Ltd.
Announced
January 2024
Price
Price not disclosed (CCI combination order)
Industry
Pharma services
Buyer type
Private equity
Fund vehicle
Majesty II Pte. Ltd.
Backing investors
PAG, Advent International, Nuvama Private Investment Trust, Ashoka India Equity Investment Trust plc
Status
Closed

By the numbers

Majesty II Pte. Ltd.'s acquisition history
1st of 1 tracked deals
Disclosed prices
0 of 1 Majesty II Pte. Ltd. deals
Tracked acquisitions in 2024
157 across all acquirers
Majesty II Pte. Ltd. in Pharma services
1 acquisition

Frequently Asked Questions About This Acquisition

When did Majesty II Pte. Ltd. acquire AI Lenarco Midco Ltd.?

Majesty II Pte. Ltd. acquired AI Lenarco Midco Ltd. on January 2024. This was Majesty II Pte. Ltd.'s 1st publicly tracked acquisition out of 1 we have on record.

How much did Majesty II Pte. Ltd. pay for AI Lenarco Midco Ltd.?

Majesty II Pte. Ltd. paid Price not disclosed (CCI combination order) for AI Lenarco Midco Ltd..

What does AI Lenarco Midco Ltd. do?

Holding company of an Indian pharma/specialty business Acquired through Majesty II Pte. Ltd., a vehicle of PAG; Advent International; Nuvama Private Investment Trust; Ashoka India Equity Investment Trust plc. Source: https://www.cci.gov.in/images/summaryorders/en/summary1733906432.pdf

What other Pharma services companies has Majesty II Pte. Ltd. acquired?

AI Lenarco Midco Ltd. is Majesty II Pte. Ltd.'s only publicly tracked acquisition in Pharma services so far.

Read the full article →